In this third week of January, we bring our readers research updates on antibiotic resistance, and how in comparison, resistance to vaccines is rare. There’s also an article giving a detailed status check on where we are as an industry in finding a medical treatment for non-alcoholic steatohepatitis (NASH). As well as this we have articles on oncology; dermatology indications such as eczema and psoriasis; and neurological conditions such as major depression, and for a rare neonatal illness - molybdenum cofactor (moco) deficiency.
Why Resistance is Common in Antibiotics, but Rare in Vaccines
Antibiotic resistance is a worldwide problem to the extent that there is a grave risk that common infections will soon become untreatable. Meanwhile, vaccines developed nearly a century ago still protect us from deadly diseases. What might explain this difference?
The Race is on for Medical Treatment of NASH
Non-alcoholic steatohepatitis is the second leading indication for liver transplantation in the United States but there are currently no FDA-approved treatments available. In the next decade NASH will likely become the no. 1 indication for liver transplantation. The increase in the prevalence and incidence of obesity and type 2 diabetes will increase the burden of liver disease in the coming decades.
Expanding Line of Therapeutic Agents for Psoriasis
Several systemic therapies are available for the treatment of patients with moderate to severe psoriasis. Continued research has further elucidated the immunopathogenesis of the disease, leading to the development of novel biologic agents that are proving to more effectively and safely address moderate to severe psoriatic lesions.
Study Shows Why Antihistamine Drugs Fail to Control Severe Itch in Eczema Patients
In addition to a skin rash, many eczema sufferers also experience chronic itching, but sometimes that itching can become torturous. Worse, antihistamines -- the standard treatment for itching and allergy -- often don't help.
Potential Pathway for Rare Neurological Disorder Discovered
Molybdenum cofactor (Moco) is a compound that is little known but is essential for life. Children born without the ability to synthesize Moco die young. However, it has not been possible to create Moco supplements because the compound is so unstable. Now researchers say they have found a potential pathway that can make Moco stable and repair deficiency, by combining Moco with certain proteins in the nematode Caenorhabditis elegans.
Targeting the Circadian Rhythm Regulator CRY-1 in Prostate Cancer
Our biological or circadian clock synchronizes all our bodily processes to the natural rhythms of light and dark. It's no wonder then that disrupting the clock can wreak havoc on our body. In fact, studies have shown that when circadian rhythms are disturbed through sleep deprivation, jet lag, or shift work, there is an increased incidence of some cancers including prostate cancer, which is the second leading cause of cancer death for men in the U.S.
Metabolism May be Able to Predict Major Depression
A new study finds that people with major depression have a widely different metabolic profile than people without depression. Most metabolic markers in people with recurrent major depressive disorder are involved in breaking down fat. The findings suggest that metabolites could be a useful tool for predicting the risk of major depressive episodes.